Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Rising demands and advancements in eye care drive growth
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Subscribe To Our Newsletter & Stay Updated
